138 related articles for article (PubMed ID: 27022050)
21. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
22. [Role of ezetimibe in secondary cardiovascular prevention finally determined?].
Lanzi D; Fumeaux T
Rev Med Suisse; 2015 Nov; 11(496):2257. PubMed ID: 26742360
[No Abstract] [Full Text] [Related]
23. [Letter].
Poli A
G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
[No Abstract] [Full Text] [Related]
24. Ezetimibe-Statin Combination to Reduce Cardiovascular Events: The Evidence Base.
Jialal I; Abate N
Metab Syndr Relat Disord; 2015 Oct; 13(8):327-8. PubMed ID: 26177147
[No Abstract] [Full Text] [Related]
25. Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome.
Toth PP
Evid Based Med; 2015 Oct; 20(5):176. PubMed ID: 26261287
[No Abstract] [Full Text] [Related]
26. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Packard C; Stezhka T
Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
[TBL] [Abstract][Full Text] [Related]
27. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
[TBL] [Abstract][Full Text] [Related]
28. [IMPROVE-IT trial. Good news for ezetimibe and for patients].
Escobar C; Divisón JA; Seguí Díaz M
Semergen; 2015; 41(5):282-3. PubMed ID: 25630369
[No Abstract] [Full Text] [Related]
29. Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Hodges GW; Bang CN; Forman JL; Olsen MH; Boman K; Ray S; Kesäniemi YA; Eugen-Olsen J; Greve AM; Jeppesen JL; Wachtell K
Atherosclerosis; 2018 May; 272():129-136. PubMed ID: 29602140
[TBL] [Abstract][Full Text] [Related]
30. [The IMPROVE-IT trial].
Menozzi A; Lina D; Urbinati S; Greco C
G Ital Cardiol (Rome); 2015 Dec; 16(12):667-71. PubMed ID: 26667942
[No Abstract] [Full Text] [Related]
31. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
32. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients.
Sager PT; Capece R; Lipka L; Strony J; Yang B; Suresh R; Mitchel Y; Veltri E
Atherosclerosis; 2005 Apr; 179(2):361-7. PubMed ID: 15777554
[TBL] [Abstract][Full Text] [Related]
33. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
34. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration.
Araujo DB; Bertolami MC; Ferreira WP; Abdalla DS; Faludi AA; Nakamura Y; Bricharello LP
J Cardiovasc Pharmacol; 2010 Jan; 55(1):1-5. PubMed ID: 19770669
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Serban MC; Banach M; Mikhailidis DP
Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
[TBL] [Abstract][Full Text] [Related]
37. Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman WH
Am J Med; 2015 Nov; 128(11):1160-1. PubMed ID: 26184685
[No Abstract] [Full Text] [Related]
38. Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT.
Jarcho JA; Keaney JF
N Engl J Med; 2015 Jun; 372(25):2448-50. PubMed ID: 26039520
[No Abstract] [Full Text] [Related]
39. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2014 Dec; 60(12):1095-101. PubMed ID: 25692840
[TBL] [Abstract][Full Text] [Related]
40. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
